Merck & Co.
MRK
$130.20
+0.32%
Merck & Co., Inc. is a global healthcare leader that develops and manufactures pharmaceuticals, vaccines, and animal health products, with a focus on therapeutic areas such as oncology, cardiometabolic disease, and infectious diseases. The company's competitive identity is anchored by its blockbuster immuno-oncology drug Keytruda, which has become a cornerstone of cancer treatment, alongside a robust vaccine portfolio including Gardasil and the recently expanded Capvaxive. Currently, the investor narrative centers on Merck's ability to navigate the looming patent cliff for Keytruda, diversify its pipeline through strategic partnerships and acquisitions, and capitalize on recent FDA label expansions for its pneumococcal vaccine, while also managing the financial impact of significant R&D investments and recent acquisition-related charges.…
MRK
Merck & Co.
$130.20
Related headlines
MRK 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Merck & Co.'s 12-month outlook, with a consensus price target around $135.19 and implied upside of +3.8% versus the current price.
Average Target
$135.19
0 analysts
Implied Upside
+3.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$105 - $155
Analyst target range
Merck is covered by 26 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.82 (where 1 is Strong Buy and 5 is Sell). The average price target is $135.19, implying a modest upside of 3.8% from the current price of $130.20. The distribution of ratings is bullish, with recent actions from firms like BMO Capital, Guggenheim, and JP Morgan reiterating 'Outperform' or 'Buy' ratings, while Morgan Stanley maintains an 'Equal Weight' stance. The target price range spans from $105.00 (low) to $155.00 (high), indicating a wide dispersion of expectations. The low target suggests concerns about the patent cliff and pipeline execution, while the high target implies confidence in new product launches and successful diversification. The relatively tight spread between the average and current price suggests analysts see limited near-term upside, but the overall bullish consensus reflects confidence in Merck's long-term strategy.
Bulls vs Bears: MRK Investment Factors
Merck presents a balanced risk/reward profile. The bull case is anchored by strong momentum, attractive valuation, and high margins, while the bear case centers on the looming Keytruda patent cliff and earnings volatility. Currently, the bull case has slightly stronger evidence given the stock's 66.7% 1-year performance and 14.4x PE discount, but the patent cliff remains the pivotal factor. If Merck successfully diversifies its pipeline, the stock could re-rate higher; if not, the valuation could compress significantly.
Bullish
- Strong momentum with 66.7% 1-year gain: MRK has delivered a 66.7% return over the past year, vastly outperforming the S&P 500's 18.2% gain. This reflects robust investor confidence in the company's growth trajectory, driven by Keytruda's continued success and pipeline progress.
- Attractive valuation with 14.4x trailing PE: At 14.4x trailing earnings, MRK trades at a 20-25% discount to the sector average of 18-20x. This valuation is near the lower end of its 2-year range (9x-23x), suggesting the market is pricing in patent cliff risks but offering a margin of safety.
- High gross margins of 81.9% in Q1 2026: Gross margin expanded to 81.9% in Q1 2026, up from 70.5% in Q4 2025, reflecting strong pricing power and product mix. This indicates the company can maintain profitability even as it invests heavily in R&D.
- FDA label expansion for Capvaxive: The FDA expanded Capvaxive's label to include at-risk children and teens, potentially broadening its market and strengthening Merck's position against Pfizer's Prevnar. This could drive incremental revenue growth in the vaccine segment.
Bearish
- Keytruda patent cliff looms: Keytruda, Merck's top-selling drug, faces patent expiration in the late 2020s, which could lead to a significant revenue decline. The company's future growth depends on pipeline replacements, but the timeline is uncertain.
- Q1 2026 net loss of $4.24B: A massive $12.56B R&D charge in Q1 2026 resulted in a net loss of $4.24B, highlighting the lumpy and risky nature of pharma R&D. This volatility could deter investors seeking stable earnings.
- Limited upside to analyst target: The average analyst price target of $135.19 implies only 3.8% upside from the current price of $130.20. This suggests the stock is fairly valued, with limited near-term appreciation potential.
- High debt-to-equity ratio of 0.96: Merck's debt-to-equity ratio of 0.96 indicates significant leverage, which could strain cash flows if interest rates rise or earnings decline. This financial risk is elevated compared to some peers.
MRK Technical Analysis
Merck's stock is in a strong uptrend, with a 1-year price change of +66.67%, significantly outperforming the S&P 500's +18.19% over the same period. The current price of $130.20 is near the upper end of its 52-week range, sitting at approximately 96.4% of the range (calculated as (130.20 - 77.53) / (135.05 - 77.53) = 0.964), indicating strong momentum and investor confidence, though it also suggests the stock may be approaching overbought conditions. The stock's beta of 0.205 indicates it is significantly less volatile than the broader market, which is atypical for a healthcare stock and may reflect its defensive characteristics.
Beta
0.20
0.20x market volatility
Max Drawdown
-11.9%
Largest decline past year
52-Week Range
$78-$135
Price range past year
Annual Return
+66.7%
Cumulative gain past year
| Period | MRK Return | S&P 500 |
|---|---|---|
| 1m | +3.9% | +0.3% |
| 3m | +16.1% | +4.0% |
| 6m | +18.1% | +8.3% |
| 1y | +66.7% | +20.2% |
| ytd | +22.3% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MRK Fundamental Analysis
Merck's revenue trajectory shows moderate growth, with Q1 2026 revenue of $16.29 billion, up 4.27% year-over-year, and a sequential increase from Q4 2025's $16.32 billion. The pharmaceutical segment, which generated $14.35 billion in Q1 2026, remains the primary growth driver, while the animal health segment contributed $1.79 billion. However, the company reported a net loss of -$4.24 billion in Q1 2026, driven by a massive $12.56 billion R&D expense, likely related to acquisitions or impairments, which contrasts sharply with the profitable quarters in 2025 (e.g., Q3 2025 net income of $5.79 billion). This volatility in earnings underscores the lumpy nature of pharma R&D spending, but the underlying revenue growth and gross margin of 81.92% in Q1 2026 (up from 70.49% in Q4 2025) indicate strong product demand and pricing power.
Quarterly Revenue
$16.3B
2026-03
Revenue YoY Growth
+4.3%
YoY Comparison
Gross Margin
81.9%
Latest Quarter
Free Cash Flow
$14.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MRK Overvalued?
Given that Merck's trailing twelve-month net income is positive (despite the Q1 2026 loss, the prior three quarters were profitable), the most appropriate valuation metric is the price-to-earnings (PE) ratio. The trailing PE is 14.42x, while the forward PE is 13.45x, suggesting the market expects earnings to grow slightly, which is consistent with a PEG ratio of 1.81. Compared to the industry average, Merck's PE is at a discount; for example, the sector average PE is typically around 18-20x, so Merck's 14.42x represents a 20-25% discount, which may be justified by the patent cliff risks for Keytruda. Historically, Merck's PE has ranged from roughly 9x to 23x over the past two years, and the current 14.42x is near the lower end of that band, indicating that the stock is not overvalued relative to its own history, but rather reflects cautious market expectations.
PE
14.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 9x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Merck's Q1 2026 net loss of $4.24B, driven by a $12.56B R&D charge, underscores the volatility of its earnings. The company's debt-to-equity ratio of 0.96 indicates high leverage, which could amplify financial stress if cash flows weaken. Additionally, revenue growth is modest at 4.27% YoY, and the heavy reliance on Keytruda for a significant portion of sales creates concentration risk. The high payout ratio of 44.8% may limit flexibility for future investments or dividend increases.